Types of Cancer We Treat

Ovarian Cancer

Our gynecologic oncologists diagnose ovarian cancer and treat it using the latest surgical procedures, including minimally invasive, robotic-assisted, and fertility-sparing approaches and clinical trials.

Our gynecologic oncologists, genetic counselors, and fertility specialists offer services for women at an increased genetic risk of developing ovarian cancer. Our experts help you carefully consider whether screening or risk-reduction surgery is right for you.

We understand how important quick decisions are in treating ovarian cancer, so we generally see you within 48 hours of your appointment request. We complement cancer care with support services, including integrative health therapies, psychological support, genetic testing, and survivorship plans.

Find a Doctor & Schedule
Diagnosis
Surgery
Fertility-Sparing Procedures
Chemotherapy & Targeted Drugs

Related News

Surgical Oncologist Advances Treatment for Women’s Cancers
Read Story
Breast Cancer Previvor Discusses Genetic Testing
Read Story
Surgery Before Chemotherapy Is Effective in Ovarian Cancers
Read Story
Why Is Ovarian Cancer Detected So Late?
Read Story
Birth Control Pills May Protect Against Gynecologic Cancers
Read Story
Gynecologic Cancers Not Tied to Higher COVID-19 Death Risk
Read Story
Many Ovarian Tumors May Originate in Two Cell Types
Read Story
New Treatment for Advanced Ovarian Cancer Shows Promise
Read Story
What You Need to Know About Treating Ovarian Cancer
Read Story
Managing the Side Effects of Chemotherapy for Ovarian Cancer
Read Story
Using Biomarkers to Guide Ovarian Cancer Treatment Decisions
Read Story
Many Pelvic Tumors in Women Start in Fallopian Tubes
Read Story

Clinical Trials and Research Studies

Phase 2

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Learn More

Phase 1

A Phase 1 bioequivalence study between the current commercial formulation & the proposed soft gel capsule formulation of talazoparib & food effect study for the proposed talazoparib soft gel capsule formulation in participants w/ advanced solid tumors

Learn More

Phase 6

A RANDOMIZED PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN/BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN/BEVACIZUMAB IN PLATINUM RESISTANT OVARIAN CANCER

Learn More

Phase 1

A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

Learn More
View All Related Clinical Trials (9)